NCT00044551已完成2 期
An Open Phase II, Multi Center Trial of BAY 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 29
研究概览
简要总结
Almost two-thirds of lymphoma cases are Non-Hodgkin's Lymphomas (NHL). NHL is a malignant process that affects lymphoid cells found both in the lymph nodes and extranodally. Incidence and mortality rates from NHL are highest in developed countries. While many patients with aggressive NHL are curable with initial anthracycline-containing regimens, the majority of patients will relapse or prove refractory to initial therapy. The prognosis of patients with disease recurrence following a multidrug regimen is also limited. The current protocol is designed to test the safety and efficacy of BAY 59-8862 in patients with Aggressive Refractory Non-Hodgkin's Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Measurable disease as defined by the presence of at least one measurable lesion - Failed at least one prior therapy or has achieved remission but has progressed or relapsed within 6 months of therapy - Life expectancy of at least 12 weeks - Adequate bone marrow, liver and kidney function
排除标准
- •Excluded medical conditions like: pre-existing neuropathy, active heart diseases or ischemia, serious infections, HIV infection, chronic hepatitis B or C, seizures, hypersensitivity to taxanes, organ transplants, some previous cancers - Excluded therapies and medications, previous and concomitant such as: anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to study entry; more than two prior anticancer chemotherapy regimens; radiotherapy during study or within 4 weeks prior to study entry; bone marrow transplant - Others: pregnant or breast-feeding patients; both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial; substance abuse, medical, psychological or social conditions that may interfere with the patient's participation
研究组 & 干预措施
Arm 1
Experimental
干预措施: Taxane (Cytotoxic, BAY59-8862) (Drug)
研究者
相似试验
已完成
2 期
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's LymphomaNon-Hodgkin LymphomaNCT01939327Institut Paoli-Calmettes34
招募中
3 期
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-cell LymphomaB-cell NonHodgkin LymphomaMantle Cell LymphomaNCT05097443Shandong Provincial Hospital130
已完成
不适用
A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of OrganochlorinesLymphoma, AIDS-RelatedLymphoma, Non-HodgkinHIV InfectionsNCT00001571National Cancer Institute (NCI)20
进行中（未招募）
不适用
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.Non Hodgkin LymphomaMarginal Zone LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaNCT06424379Hospices Civils de Lyon135
已完成
2 期
Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.Diffuse, Large B-Cell, LymphomaNCT01848132Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea121